Difference between revisions of "Economic evaluation"

From Testiwiki
Jump to: navigation, search
m
m
Line 366: Line 366:
 
sum_table2 <- data.frame(
 
sum_table2 <- data.frame(
 
Vaccine = qorder,
 
Vaccine = qorder,
QALYs_gained,
+
QALYs_gained__ = QALYs_gained,
Incremental_effect = QALYs_incremental,
+
Incremental_effect__ = QALYs_incremental,
Health_care_costs = Cost_total,
+
Health_care_costs__ = Cost_total,
Increm_cost = Cost_incremental,
+
Incremental_cost__ = Cost_incremental,
ICER = ICER2
+
ICER__ = ICER2
 
)
 
)
  
Line 376: Line 376:
 
sum_table2,
 
sum_table2,
 
include.rownames = FALSE,  
 
include.rownames = FALSE,  
caption = "Cost effectiveness analysis",  
+
caption = "Cost-effectiveness analysis",  
 
caption.placement = "top"
 
caption.placement = "top"
 
)
 
)

Revision as of 19:46, 19 August 2014

Progression class
In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed:
This page is a draft
The relevat content and structure of the page is already present, but there still is a lot of missing content.
This page needs a curator. Learn more about curating Opasnet pages.

Question

How to identify the most cost-effective pneumococcal conjugate vaccine to the national immunisation programme?

  • The health benefit (effectiveness) of the pneumococcal infant immunisation programme is assessed by the expected gain in Quality-Adjusted Life Years (QALYs), corresponding to the expected reduction in the annual number of invasive pneumococcal disease in the whole Finnish population.
  • The perspective of the analysis is that of the health care provider.
  • The analysis is based on incremental cost effectiveness


Answer

The answer to the question is based on the concept of incremental costs. For example, if there are only two vaccines to be compared, the more effective (and more expensive vaccine) is said to be more cost-effective if the incremental cost effectiveness ratio (ICER), comparing the vaccine to the less effective vaccine, exceeds the ICER of the less effective vaccine as compared to the alternative 'no vaccination'. The principle in general is explained below (see 'Rationale').

For the example of two vaccine, ICERs can be calculated with a programme code (see 'Rationale').


Rationale

Vaccination programmes are ranked according to their effectiveness (V1 < V2 < V3, etc.). Effectiveness is measured as reduction in invasive pneumococcal disease. Vaccination programmes that are more expensive and less effective as compared to at least one other alternative (i.e. are strongly dominated) are excluded. Incremental cost-effectiveness ratios (ICER) are calculated for the remaining vaccines:

Failed to parse (Missing <code>texvc</code> executable. Please see math/README to configure.): ICER = \frac{(C_2-S_2) - (C_1-S_1)}{E_2-E_1},

where C is the price of the vaccination program,
S is the savings in health care costs and
E is the savings in QALYs.

Each vaccine (ranked according to their effectiveness) is compared with the next highest ranked vaccine. The least effective vaccine is compared with doing nothing. The most cost-effective vaccine is determined.


Costs

Health care resource use in secondary health care per IPD case and sequelae after meningitis were estimated from Hospital Discharge Register (2000-2006). For each meningitis and bacteremia case, an episode of care was constructed by linking the outpatient visits and inpatient hospitalizations using the unique personal identity code. The case fatality ratio (CFR) for IPD was obtained from a Finnish study [Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti P. Incidence and outcome of invasive Streptococcus pneumonia infections, Finland, 1995 /2002. In: The 4th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 2004 May 9 /13 2004; Helsinki; 2004.]. The unit costs for hospitalizations and outpatient visits were estimated based on individual-level cost accounting data from one hospital district. Other unit cost estimates were mainly taken from a widely used national price list for the unit costs of health care in Finland. The costs were presented in 2012 prices and were evaluated from the health care provider perspective. The future costs and benefits were discounted at 3% per annum.

Calculations

The following code can be used to calculate the incremental cost effectiveness ratios (ICERs) for two alternative vaccination programmes (by default PCV10 and PCV13; other options can be defined by the user). The input required from the user is simple:

(a) the serotype compositions of the two vaccines to be compared (default PCV10 and PCV13), and (b) the prices per dose for the two vaccine products.

The computation utilises the epidemiological model to predict the annual number of invasive pneumococcal disease (IPD) under both vaccination programmes and, for comparison, for the scenario 'no vaccination'. The summary table presents the ICERs. All population-level results correspond to the Finnish population (5.4 million people).


# : Code works but the costs seem unrealistic. --Jouni (talk) 05:49, 11 August 2014 (UTC)

Scenarios

Please choose the vaccines to be compared::
PCV-10
PCV-13

What is the price of a single PCV10 vaccination?:

What is the price of a single PCV13 vaccination?:

Do you want to adjust PCV-10 or PCV-13 vaccine composition?:

Debug plots:
Show all

User defined vaccine

Choose the serotypes for the PCV-10 vaccine composition:
1
3
4
5
6A
6B
6C
7F
8
9N
9V
10
11
12
14
15
16
18C
19A
19F
20
22
23A
23F
33
35
38
Other

Choose the serotypes for the PCV-10 vaccine composition:
1
3
4
5
6A
6B
6C
7F
8
9N
9V
10
11
12
14
15
16
18C
19A
19F
20
22
23A
23F
33
35
38
Other

+ Show code


Variable initiation

+ Show code

Cost calculation

+ Show code

Data

Show results


See also

Tendering process for pneumococcal conjugate vaccine
Parts of the assessment

Comparison criteria for vaccine   · Epidemiological modelling   · Economic evaluation

Background information

Sensitivity analysis · Replacement   · Pneumococcal vaccine products   · Finnish vaccination schedule   · Selected recent publications


Help for discussion and wiki editing

Pages in Finnish

Pneumokokkirokotteen hankinta  · Rokotteen vertailuperusteet · Epidemiologinen malli · Taloudellinen arviointi · Pneumokokkirokotteen turvallisuus


Work scheduling · Monitoring the effectiveness of the pneumococcal conjugate vaccine · Glossary of vaccine terminology


References


Comment the content

Current comments that have not yet been included in the main page or talk page.


You can give comments about the content without login simply by writing your comments into the text box below. The page moderator will include your comments in the actual content of the page and then moves the comment to the archive: Show results


Your comment about the page content or discussion:

To what part of the page does you comment refer?:

Comments to be removed (after they have been moved to the page text)

ID of the comment to be removed:

Reason to remove: